ANGLE PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21 GBX | -10.64% |
|
+18.31% | +78.72% |
| 05-03 | Angle shares up on assay development deal with AstraZeneca | AN |
| 05-03 | Angle shares up on assay development deal with AstraZenaca | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
ANGLE plc is a United Kingdom-based liquid biopsy company with circulating tumor cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. Its circulating tumor cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample, including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. The Parsortix PC1 system is a medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for user-validated analysis. Its commercial businesses focus on diagnostic products and clinical services. Its diagnostic products include the Parsortix system and associated consumables. Its services include custom made assay development and clinical trial testing for pharma. The Parsortix technology uses a microfluidic technology in the form of a single use cassette to capture and then harvest CTCs from whole blood.
Calendar
25/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.235
GBP
Average target price
0.685
GBP
Spread / Average Target
+191.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +78.72% | 76.6M | |
| -16.33% | 18.83B | |
| -43.15% | 2.92B | |
| +22.02% | 1.9B | |
| +0.39% | 1.71B | |
| +27.15% | 1.26B | |
| -10.70% | 1.04B | |
| -18.27% | 961M | |
| +0.66% | 779M | |
| -25.85% | 649M |
- Stock Market
- Equities
- AGL Stock
- News ANGLE plc
- Angle plc Secures European Patent for CellKeep Technology
